Episode 126: Exploring the Therapeutic Potential of ATH434 in Multiple System Atrophy

Episode 126 of the NeurologyLive^® Mind Moments^® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

In this episode, "Exploring the Therapeutic Potential of ATH434 in Multiple System Atrophy" we're joined by Daniel Claassen, MD, MS, a professor of neurology and chief of the Behavioral and Cognitive Neurology Division at Vanderbilt University Medical Center, who offered his insight on phase 1/2 data that was recently presented at the International Parkinson and Movement Disorder Society (MDS) Congress on ATH434, an investigational drug in development from Alterity Therapeutics for multiple system atrophy (MSA). He dove into the therapy's mechanism of action and the currently known safety profile and considerations for its use, as well as the next steps in advancing care for patients with MSA as a whole.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA Removes Partial Hold for Myotonic Dystrophy Agent AOC 1001
• FDA Approves Avadel's Sodium Oxybate for Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy
• FDA Approves AbbVie’s 24-Hour Foscarbidopa/Foslevodopa Pump for Advanced Parkinson Disease Treatment

EPISODE BREAKDOWN

• 1:10 – Overviewing the conduct of the phase 1/2 studies
• 3:00 – Notable findings from data presented at MDS
• 4:30 – Mechanism of action behind ATH434
• 8:20 – Neurology News Minute
• 10:20 – Next steps in ATH434's development
• 11:15 – Current unmet needs for patients with MSA

Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

• Click here for Apple Podcasts
• Click here for Spotify
• Click here for Google Podcasts